1. Home
  2. SLDB vs LXRX Comparison

SLDB vs LXRX Comparison

Compare SLDB & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

HOLD

Current Price

$8.35

Market Cap

498.6M

Sector

Health Care

ML Signal

HOLD

LXRX

Lexicon Pharmaceuticals Inc.

HOLD

Current Price

$1.84

Market Cap

660.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLDB
LXRX
Founded
2013
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
498.6M
660.9M
IPO Year
2017
2000

Fundamental Metrics

Financial Performance
Metric
SLDB
LXRX
Price
$8.35
$1.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
2
Target Price
$16.36
$4.15
AVG Volume (30 Days)
1.0M
2.3M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
34.97
77.78
EPS
N/A
N/A
Revenue
$8,094,000.00
$49,803,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
60.24
52 Week Low
$2.51
$0.49
52 Week High
$8.87
$1.86

Technical Indicators

Market Signals
Indicator
SLDB
LXRX
Relative Strength Index (RSI) 61.55 64.14
Support Level $5.16 $1.07
Resistance Level N/A N/A
Average True Range (ATR) 0.58 0.10
MACD 0.06 0.02
Stochastic Oscillator 78.26 90.00

Price Performance

Historical Comparison
SLDB
LXRX

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Share on Social Networks: